Plasma Derived Medicine Market By Product Type (Immunoglobulins (Ig), Coagulation Factors, Albumin, C1 Esterase Inhibitors, Fibrinogen Concentrates, Other), By Application (Immunology, Haematology, Critical Care, Pulmonology, Neurology, Infectious Diseases, Other), By Delivery Mode (Intravenous, Subcutaneous, Topical), By End-User (Hospitals, Clinics, Blood & Plasma Donation Centers, Diagnostic Laboratories, Academic and Research Institutes), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Plasma Derived Medicine market accounted for USD 17.3 Billion in 2024 and is expected to reach USD 41.38 Billion by 2035, growing at a CAGR of around 8.25% between 2025 and 2035. The Plasma Derived medicine market is described as the business of producing and selling therapeutic drugs derived from human plasma. These drugs are used to treat a wide range of health issues, including hemophilia, immunological deficits, and autoimmune illnesses, to name a few. This market comprises clotting factors, immunoglobulins, albumin, and other specialty product categories.

The market has expanded with the aid of biotechnology development, existing demand for such therapies, and the growing appreciation of plasma donation in medicine. Further, the operation of this market depends on factors like regulatory norms, plasma collection, and the requirements of the global market.

Report Scope:

Market Dynamics

Growing demand for immunoglobulins for immunodeficiencies and autoimmune disease treatments across regions

The Plasma Derived medicine market is experiencing a rising demand for immunoglobulins, which are crucial for treating immunodeficiencies and autoimmune diseases and for saving lives with primary immunodeficiency diseases who cannot synthesize antibodies as required by the body. Used in autoimmune diseases, such as Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP), they are critical weapons in the current arsenal of treatments in today’s medical practice.

This demand is exacerbated by innovations and the expanding healthcare system. According to the present invention, subcutaneous immunoglobulin formulations are breakthrough advancement in the therapeutic field because they are more convenient for patients and have fewer adverse effects. Furthermore, the government encourages investment in plasma collection facilities to ensure continuous supply and market sustainability.

Rising prevalence of rare diseases requiring Plasma Derived therapies like hemophilia and CIDP

The Plasma Derived medicine market is growing as more people are diagnosed with rare diseases like hemophilia or chronic inflammatory demyelinating polyneuropathy (CIDP). These patients often need plasma-based therapies that are symptomatic and can greatly enhance their quality of life. For instance, hemophilia is managed using coagulation factors derived from plasma, which has greatly reduced fatal bleeding occurrences. Intravenous immunoglobulins (IVIG) are important for CIDP because they help lessen inflammation and appear to repair damaged nerves.

Other factors and supportive government policies add extra strength to the market's growth in innovative ways. New-generation plasma products and novel coagulation factors mean sustained and more effective therapies for certain rare diseases. Moreover, the global initiatives to enhance plasma collection networks and their processes ensure an unhampered supply of raw plasma. The Plasma Derived medicine industry is set to expand with one of the most promising industries to solve major medical issues with modern therapeutic products.

High costs of Plasma Derived treatments limiting accessibility in low-income patient populations

The high costs of these Plasma Derived medicines provide a significant barrier to fair access for low-income patient populations. These medications contain immunoglobulins, coagulation factors, and other treatments that necessitate advanced plasma collection and purification processes, increasing production costs. Further, the need to collect abnormally huge amounts of plasma grows, and some regimens may require thousands of donors. This economic burden affects people in low-income areas since healthcare costs and insurance coverage are insufficient to pay for life-saving medications.

Organizations and governments are attempting to expand plasma supply by implementing efficient and cost-effective technologies including recombinant plasma alternatives and advanced fractionation processes. However, many innovations need time to attain their full potential and reach out to underserved people. Key stakeholders and pharmaceutical manufacturers must collaborate to provide low-cost Plasma Derived medicines that are available to everyone, regardless of socioeconomic status.

Advancements in purification technologies to enhance plasma product efficacy and safety globally

These purifying technology innovations have improved the efficiency and safety of the global Plasma Derived medication market. These developments include revolutionary techniques like nanofiltration, enhanced chromatography, and improved fractionation. They increase the effectiveness and consistency of treatment and the trust of healthcare practitioners and patients in the Plasma Derived medicine market.  The utilization of these innovative purification procedures also promotes the development of more Plasma Derived medicinal products.

The rational use of plasma results in minimum waste and certain significant supply chain challenges that are commonly encountered by enterprises around the world are also addressed. For instance, the current generation of fractionation devices may fractionate and extract many types of plasma simultaneously while maintaining high yields and low costs. Combined with rules requiring high levels of safety for plasma products, innovations like these position the Plasma Derived pharmaceutical sector for increased global usage. Such technologies can be incorporated to significantly improve the healthcare system by offering safe and effective rare and chronic illness treatments around the world.

Growing adoption of Plasma Derived therapies in emerging markets with developing healthcare infrastructure

The Plasma Derived medicine market is on the rise due to enhanced usage in the emerging economy supported by increasing healthcare facilities. It is noteworthy that plasma-based treatments, which were previously unavailable to many countries, are gradually opening up in Asian and Latin American countries, and in some African countries. With the advancement of these healthcare systems, cost-effective treatments such as immunoglobulins, coagulation factors, and albumin are also getting access. Such therapies are increasingly being considered necessary for the treatment of some rare diseases and immunological disorders, thereby stimulating the development of this market.

The growing adoption is accompanied by the investment from global pharmaceutical giants' interest in entering these potentially huge markets. Organizations are coming together with the local administrations to increase the yield of plasmas and the standards of the facilities. This guarantees the security of Plasma Derived medicine and influences the improvement of the healthcare system in these areas. New markets will remain important for the future growth of the Plasma Derived medicine industry, as new markets offer Plasma Derived medicine solutions for previously untapped populations.

Industry Experts Opinion

“We’re working hard to make sure that all the stakeholders understand the value that Plasma Derived drugs bring to the table.” What’s more, they need to recognize that sometimes these types of products may need different considerations, as they are not traditional pharmaceuticals. If they understand and respect lead times where possible, then it’s much easier to make sure we meet the demands of the patients that require the product.”  

• Lutz Bonacker, the company’s senior vice president and general manager, CSL Behring.

“I think oftentimes patients with some of these rare and chronic diseases are deficient in certain vital proteins that play roles like fighting disease and clotting blood. And so, where these proteins are deficient and we can extract those proteins naturally from human plasma through the fractionation process, those kinds of diseases are good candidates for treatment with Plasma Derived therapy.”

• Giles Platford, president of the Plasma Derived Therapies Business Unit at Takeda.

Segment Analysis

Based on product type, the Plasma Derived Medicine Market is classified into Immunoglobulins (Ig), Coagulation Factors, Albumin, C1 Esterase Inhibitors, Fibrinogen Concentrates, and Other. In the Plasma Derived medicine market, immunoglobulins (Ig) encompass a large and dominating segment of this market. Antibodies known as immunoglobulins, particularly intravenous immunoglobulins (IVIG), are commonly used in the treatment of autoimmune illnesses, immunodeficiencies, and inflammatory disorders. As the prevalence of autoimmune diseases rises, so does awareness of IVIG, which is predicted to be the major revenue generator in this market owing to its global availability of therapy. Because of the beneficial outcomes of PRP use in a variety of settings, ranging from acute instances to chronic conditions, and clinical effectiveness confirmation, its demand in the Plasma Derived therapies market will stay high.

Based on application, the Plasma Derived Medicine Market is classified into Immunology, Haematology, Critical Care, Pulmonology, Neurology, Infectious Diseases, and Other. Immunology is the largest and most exceptional section of the Plasma Derived medicine market. This appears to be related to immunoglobulins (IVIg), which are used to treat a variety of immunological deficiencies, autoimmune disorders, and inflammation. Immunoglobulin therapies are beneficial in illnesses such as primary immunodeficiencies and autoimmune disorders, including rheumatoid arthritis and neurologic disorders such as Guillain-Barré syndrome. Furthermore, rising immunoglobulin therapy trends, and advances in plasma fractionation technology, have propelled immunology to the top of the Plasma Derived medical product market.

Regional Analysis

The North American Plasma Derived medicine market is leading because of the developed infrastructure for health care, awareness about new treatment techniques, and sound collection of plasma. The United States holds the largest market share in the region due to the rising use of immunoglobulins, coagulation factors, and albumin for many rare and chronic diseases. The latest achievements include new techniques in selecting plasma fractions and recombinant products from such leading producers as CSL Behring and Takeda. Moreover, the growing demand for personalized medicine and advanced therapies is fueling market growth. The presence of robust regulatory frameworks and ongoing research into Plasma Derived therapies further supports the expansion of the market in North America.

The Asia-Pacific Plasma Derived medicine market is the fastest growing due to advances in healthcare infrastructure, increased awareness of rare diseases, and a desire for less expensive treatment options. It has been fueled by large populations, particularly in China and India, and government efforts to strengthen plasma donation procedures. Some recent changes include investments in domestic plasma collection facilities and cost leadership in therapeutic manufacture by regional players like China Biologic Products Holdings.

Developing partnerships between international and domestic firms to address unmet demand for healthcare services is intended to develop a stable supply chain and enhance market growth rates. Furthermore, government initiatives and increased investment in healthcare research are hastening the implementation of Plasma Derived medicines in the region. The growing patient population with chronic illnesses and immunodeficiencies is boosting demand for these treatments throughout Asia-Pacific.

Competitive Landscape

The Plasma Derived medicine market is considered to have fairly high competition, where several participants occupy the leading positions in the industry. Major players are CSL Behring, Takeda Pharmaceutical Company Limited, Grifols, S.A., Octapharma, Kedrion Biopharma, Baxter International Inc., Biotest AG, and ADMA Biologics. They are gradually moving forward due to product development and acquisition strategies.

For instance, CSL Behring has recently added new therapies for immunodeficiencies into its product line, and Grifols has been increasing capacity through the addition of new plasma centers. Further, market trends like Takeda's focus on rare illness drugs and Baxter's improvements in hemophilia therapy are slowing market growth. Demand is also driving an increase in plasma collection infrastructure investment, resulting in a market growth rate, with players such as Kedrion Biopharma rapidly expanding across the global market.

Plasma Derived Medicine Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In April 2024, Kedrion Biopharma Inc., an international biopharmaceutical company specializing in the research and development, production, and commercialization of Plasma Derived therapeutic products used in treating rare and serious diseases, announced plasminogen deficiency type 1 (PLGD-1) patients in the U.S. now have access to RYPLAZIM® (plasminogen, human-tvmh).
• In January 2024, CSL Behring, a business unit of global biotechnology leader CSL, today announced the availability of 4and 5-gram vial sizes for ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)]. Previously available only in a 1-gram vial, the 4- and 5-gram packaging is significant for the Alpha-1 community as it will streamline the preparation process for ZEMAIRA and reduce waste.

Report Coverage:

By Product Type

• Immunoglobulins (Ig)
• Coagulation Factors
• Albumin
• C1 Esterase Inhibitors
• Fibrinogen Concentrates
• Other

By Application

• Immunology
• Haematology
• Critical Care
• Pulmonology
• Neurology
• Infectious Diseases
• Other

 By Delivery Mode

• Intravenous
• Subcutaneous
• Topical

By End User

• Hospitals
• Clinics
• Blood & Plasma Donation Centers
• Diagnostic Laboratories
• Academic and Research Institutes

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• CSL Behring
• Takeda Pharmaceutical Company Limited
• Grifols, S.A.
• Octapharma
• Kedrion Biopharma
• Baxter International Inc.
• Biotest AG
• ADMA Biologics
• Bio Products Laboratory Ltd
• Kamada Pharmaceuticals
• SK Plasma
• Taibang Biological Group Co., Ltd.
• Arthrex, Inc.
• Johnson & Johnson
• Shanghai RAAS Blood Products Co., Ltd.
• China Biologic Products Holdings, Inc.
• LFB Group
• Antaris Pharma

Frequently Asked Questions (FAQs)